Literature DB >> 9765303

The mechanism of inhibition of topoisomerase IV by quinolone antibacterials.

A B Khodursky1, N R Cozzarelli.   

Abstract

Topoisomerase IV (Topo IV) is a mediator of quinolone toxicity in bacteria. In this work, we demonstrate that norfloxacin, a model quinolone, converts Escherichia coli Topo IV into a poisonous adduct on DNA as opposed to inhibiting topoisomerase activity. Norfloxacin inhibition of Topo IV induces a slow decline in DNA synthesis that parallels cell death. Treatment of cells with a lethal concentration of the antibacterial did not block chromosome segregation, the phenotype of catalytic inhibition of Topo IV. Instead, norfloxacin causes DNA damage, as evidenced by the induction of the SOS pathway for DNA repair; the increase in susceptibility to the drug by mutations in genes for DNA repair pathways including recA, recB, and uvrD; and the efficient detergent-induced linearization of plasmid DNA in drug-treated cells. Wild-type and drug-resistant alleles of Topo IV are co-dominant, but we find that mutations in recA, seqA, or gyrB result in unconditional dominance of the sensitive allele, the characteristic of a poisoning mode of inhibition. These mutations either compromise chromosome integrity or force Topo IV to play a more active role in DNA unlinking in front of the replication fork. We interpret our results in terms of distinct but complementary roles of Topo IV and gyrase in DNA replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765303     DOI: 10.1074/jbc.273.42.27668

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Analysis of topoisomerase function in bacterial replication fork movement: use of DNA microarrays.

Authors:  A B Khodursky; B J Peter; M B Schmid; J DeRisi; D Botstein; P O Brown; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  Modulation of UvrD helicase activity by covalent DNA-protein cross-links.

Authors:  Anuradha Kumari; Irina G Minko; Rebecca L Smith; R Stephen Lloyd; Amanda K McCullough
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

6.  De Novo Characterization of Genes That Contribute to High-Level Ciprofloxacin Resistance in Escherichia coli.

Authors:  Thu Tran; Qinghong Ran; Lev Ostrer; Arkady Khodursky
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  Philip Chung; Patrick J McNamara; Jeffrey J Campion; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

8.  Structural and functional divergence of MutS2 from bacterial MutS1 and eukaryotic MSH4-MSH5 homologs.

Authors:  Josephine Kang; Shuyan Huang; Martin J Blaser
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

9.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.